99% Purity CAS 188627-80-7 Eptifibatide Peptides Powder Eptifibatide Acetate Raw Powder Eptifibatide

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Eptifibatide
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Eptifibatide
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 188627-80-7
• Mf: C35h49n11o9s2
• MW: 831.96
• Einecs No.: 1312995-182-4
• Density: 1.6
• Refractive Index: 1.735
• Solubility: in Water, 1108 Mg/L at 25 C (Est)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 1 Ton/Month

Product Description

99% Purity CAS 188627-80-7 Eptifibatide Peptides Powder Eptifibatide Acetate Raw Powder Eptifibatide

 

Product Description

Product Details

Product Name	Eptifibatide
Appearance	White to off-white Powder
CAS No.	188627-80-7
MF	C35H49N11O9S2
MW	831.96

Eptifibatide is a platelet glycoprotein b/a receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur .  It has Strong effect and high selectivity .  It has no antigenicity,and it does not cause allergic reactions.  It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction.  It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events.  It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance.

Application & Function

Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor (platelet factor I receptor) antagonist.  By selectively and reversibly inhibiting the final common pathway of platelet aggregation (plasma coagulation factor I binds to GPIIb/IIIa), the ischemic state due to thrombosis can be reversed.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin.  Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodi should be employed as indicated.  Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Specification